1 in 5 Claims Denied. $867.5M Spent to Keep It That Way.

One in five health insurance claims filed through HealthCare.gov in 2023 was denied. In a 2024 AMA survey, 8% of physicians reported a patient death, disability, or permanent bodily damage linked to prior authorization delays. An estimated 100 million Americans carry medical debt. Americans pay two to four times more for prescription drugs than people in other wealthy countries.

The industry operating that system spent $867.5 million lobbying Congress in 2025, the largest lobbying sector in the US economy every year since 1999. Those numbers are usually reported as separate problems: one's a healthcare quality crisis, the other's a campaign finance story. Trace specific lobbying dollars to specific votes to specific outcomes and the connection is direct.

This is Part 3 in the Universal Healthcare in America series. Part 1 covered how employer-based insurance became the American default by accident; Part 2 covered the five reform attempts that died and who killed each one. This piece names the money behind those deaths.

The Congressman Who Banned Price Negotiation

In 2003, Congress passed the Medicare Modernization Act, creating the Part D prescription drug benefit. Buried in the law was a provision called the "noninterference clause": the government "may not interfere with the negotiations between drug manufacturers and pharmacies" and "may not require a particular formulary or institute a price structure." In plain language, Medicare was banned from negotiating drug prices.

The Congressional Budget Office estimated this single clause costs American taxpayers $11 billion per year.

The congressman who shepherded that bill through the House was Billy Tauzin, chair of the House Energy and Commerce Committee, which oversees the pharmaceutical industry. On January 3, 2005, the day after his congressional term ended, Tauzin started work as president of PhRMA, the drug industry's lobbying group, at an estimated $2 million per year.

The industry then spent 19 years defending that clause. When Congress finally passed limited Medicare drug price negotiation through the Inflation Reduction Act in 2022, it was narrowed to just 10 drugs, with a 9-to-13-year market exclusivity period before negotiation can begin. PhRMA filed lawsuits to block even that. The pharmaceutical and health products sector spent $6.1 billion in cumulative federal lobbying from 1999 through 2024 to hold that line.

The Senator Who Killed the Public Option

During the ACA debate in 2009, Senator Joe Lieberman of Connecticut threatened to filibuster any bill containing a public insurance option. As the 60th and decisive vote for cloture, his position was determinative. Democrats dropped the public option in December 2009.

Connecticut is the insurance capital of the United States. Aetna and Cigna are headquartered there. Over his career, Lieberman received more than $1 million in insurance industry contributions.

The public option would have created a government-run insurance plan competing directly with private insurers, applying downward pressure on premiums and administrative costs. Without it, private insurers face no public competitor. A 2017 study in the Annals of Internal Medicine found US insurers and providers spent $812 billion on administration that year, 34.2% of national health expenditures. Canada spent 17.0%. Private insurance overhead ran approximately 17%, versus 2-5% for traditional Medicare and Medicaid, and those ratios have had 16 years to compound.

The Reform That Passed the House and Died

In 2022, the Improving Seniors' Timely Access to Care Act passed the House of Representatives 378 to 46. The bill would have required Medicare Advantage plans to adopt electronic prior authorization, deliver real-time decisions for routine services, and report their denial rates transparently. It died in the Senate.

CMS issued its own prior authorization rule in January 2024, requiring faster turnaround on decisions and specific denial reasons. After industry comment, CMS pushed the compliance deadline from January 2026 to January 2027.

While the bill died and the rule got delayed, the system it was designed to fix kept running. Medicare Advantage insurers denied 3.2 million of over 50 million prior authorization requests in 2023. 93% of physicians say prior auth causes care delays, and 29% have reported a serious adverse patient event. 8% have reported a patient death, disability, or permanent bodily damage. The House voted 378-46 to start fixing this, and three years later the compliance deadline is still a year out.

The Revolving Door Is the Mechanism

Tauzin's path from lawmaker to industry lobbyist is the archetype, but it's systematic. A 2023 Health Affairs study found that 53% of CMS political appointees from 2004 to 2020 left for industry jobs. CMS sets Medicare reimbursement rates, approves Medicare Advantage plans, and oversees prior authorization — including the rule that just got delayed a year. Seema Verma, CMS Administrator under Trump, took a position at Oracle after leaving. Marilyn Tavenner, CMS Administrator from 2013 to 2015, had spent 25 years at for-profit hospital chain HCA before joining the agency.

The HHS Office of Inspector General estimated in 2024 that $7.5 billion in Medicare Advantage payments for 2023 were based on diagnoses not confirmed in actual service records. UnitedHealth received approximately $3.7 billion of those questionable payments. CMS corrects risk scores by less than 6%, though MedPAC estimates they're inflated by approximately 20%. The agency tasked with correcting those payments is staffed by people who may be planning their next career move at the companies receiving them.

The Scale of What's Protected

UnitedHealth Group posted $447.6 billion in revenue in 2025. CEO compensation: $26.3 million, 348 times the median employee. The health sector made $429.6 million in campaign contributions in the 2024 cycle, and 100% of Senate incumbents running that year received insurance industry money. The contribution split has flipped from 65% Republican in 2002 to 62.7% Democrat in 2024 — it moves toward whichever party is closest to passing something.

In July 2025, the One Big Beautiful Bill Act cut Medicaid by $1 trillion over 10 years. The industry spent $109 million more on lobbying than the year before and still couldn't stop the cuts. But per-capita Medicaid caps didn't pass, and ACA expansion rollback didn't pass: the structural pieces that would actually change how revenue flows.

57% of Americans say the government should ensure healthcare coverage. After the December 2024 killing of UnitedHealthcare CEO Brian Thompson, roughly 7 in 10 adults said insurance profits and coverage denials bore responsibility. Part 4 of this series looks at what all of that produces in actual health outcomes.